NGEN
What one share of Nervgen Pharma holds
Pharmaceutical Preparations
On February 14, 2023, we announced that we had completed dosing of all subjects in the NVG-291 Phase 1 clinical trial and that we planned to initiate a Phase 1b/2a clinical trial of NVG-291 in individuals with SCI in Q3 2023.
Nervgen Pharma’s numbers from its SEC filings, divided by its shares. Results cover the latest fiscal year to 2025-12-31; the balance sheet is as of 2025-12-31.
| Profit | −$0.44 |
|---|---|
| Cash and investments | $0.20 |
| Book value | $0.03 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2024 | — | −$0.26 | — | −$0.18 | — | $0.03 |
| 2025 | — | −$0.44 | — | −$0.19 | — | $0.03 |